Intellia Therapeutics, Inc.
Stock Details
Is it expensive?
Trailing P/E Ratio
-3.69
Forward P/E Ratio
-7.65
PEG Ratio
0.14
-3.93
Price-to-Sales (TTM)
29.74
2.73
5.16
Market Cap
1.97B
1.62B
Is it profitable?
Net Profit Margin (TTM)
0.00%
Gross Profit Margin
0.00%
Diluted EPS (TTM)
-3.52
-56.34%
66.09M
Is it growing?
-9.50%
-9.50%
Is it risky?
1.93
12.96
6.10
80.49M
Who owns it?
76.76%
3.83%
46.78%
120.45M
134.16M
Does it pay?
0.00%
0.00%
--
--
How much cash?
375.99M
-363.15M
-235.23M
2.69
- Price
- 14.07
- Percent Change
- +0.39 (2.85%)
- Previous Close
- 13.68
- Open
- 13.71
- Low
- 13.13
- High
- 14.29
52-Week Range Position (52WRP)
Below Average
Below Average
within its 1-year price range
$14.07
From 52W Low
+106.00%
From 52W High
-50.19%
Today
+2.85%
1Y Change
+104.80%
6M
$8.42
3M
$15.44
1M
$13.48
Today
$14.07
From 52W Low
+106.00%
From 52W High
-50.19%
Today
+2.85%
1Y Change
+104.80%
6M
$8.42
3M
$15.44
1M
$13.48
Today
$14.07
Below Average
within its 1-year price range
$14.07
Multi-Timeframe Analysis (MTA)
Uptrend
Most timeframes point up. One conflicting period introduces some uncertainty, but the overall direction is positive. Weaker than a Strong Uptrend, but still a bullish signal. As reflected in the Multi-Timeframe Analysis (MTA) below.
1M
+4.4%
3M
-8.9%
6M
+67.1%
1Y
+104.8%
Rate of Change (ROC)
Weakening
Price is rising, but slower than usual. As reflected in the ROC Momentum below, which compares recent monthly gain vs its 12-month average pace.
Relative Volume (RVOL)
Low Volume
Very little activity today. Thin trading can exaggerate price moves in either direction. As reflected in the Relative Volume (RVOL) below.
- Name
- Intellia Therapeutics, Inc.
- Founded
- 2014
- CEO
- John M. Leonard
- Employees
- 377
- Fiscal Year End
- Dec 31, 2024
- Address
57 Cambridge Parkway, Suite 200A
Cambridge
Massachusetts
02142
United States
- GICS Classification
- Health Care›Pharmaceuticals, Biotechnology & Life Sciences›Biotechnology
- Website
- www.intelliatx.com
Indicators
Operating Cash Flow
-363.15M
Net Income
-394.60M
Backed by Cash
0.92
Earnings closely match operating cash flow. This is the healthy baseline: profits are genuine and not artificially inflated.
Most investors only look at net income, which companies can manipulate through accounting rules. Cash flow is harder to fake. A ratio above 1.0 means every dollar of profit is backed by real cash.
Related Heatmaps
Cathie WoodPortfolio ARK Investment Management |
Indicators
Operating Cash Flow
-363.15M
Net Income
-394.60M
Backed by Cash
0.92
Earnings closely match operating cash flow. This is the healthy baseline: profits are genuine and not artificially inflated.
Most investors only look at net income, which companies can manipulate through accounting rules. Cash flow is harder to fake. A ratio above 1.0 means every dollar of profit is backed by real cash.
Stock Details
Is it expensive?
Trailing P/E Ratio
-3.69
Forward P/E Ratio
-7.65
PEG Ratio
0.14
-3.93
Price-to-Sales (TTM)
29.74
2.73
5.16
Market Cap
1.97B
1.62B
Is it profitable?
Net Profit Margin (TTM)
0.00%
Gross Profit Margin
0.00%
Diluted EPS (TTM)
-3.52
-56.34%
66.09M
Is it growing?
-9.50%
-9.50%
Is it risky?
1.93
12.96
6.10
80.49M
Who owns it?
76.76%
3.83%
46.78%
120.45M
134.16M
Does it pay?
0.00%
0.00%
--
--
How much cash?
375.99M
-363.15M
-235.23M
2.69
- Price
- 14.07
- Percent Change
- +0.39 (2.85%)
- Previous Close
- 13.68
- Open
- 13.71
- Low
- 13.13
- High
- 14.29
52-Week Range Position (52WRP)
Below Average
Below Average
within its 1-year price range
$14.07
From 52W Low
+106.00%
From 52W High
-50.19%
Today
+2.85%
1Y Change
+104.80%
6M
$8.42
3M
$15.44
1M
$13.48
Today
$14.07
From 52W Low
+106.00%
From 52W High
-50.19%
Today
+2.85%
1Y Change
+104.80%
6M
$8.42
3M
$15.44
1M
$13.48
Today
$14.07
Below Average
within its 1-year price range
$14.07
Multi-Timeframe Analysis (MTA)
Uptrend
Most timeframes point up. One conflicting period introduces some uncertainty, but the overall direction is positive. Weaker than a Strong Uptrend, but still a bullish signal. As reflected in the Multi-Timeframe Analysis (MTA) below.
1M
+4.4%
3M
-8.9%
6M
+67.1%
1Y
+104.8%
Rate of Change (ROC)
Weakening
Price is rising, but slower than usual. As reflected in the ROC Momentum below, which compares recent monthly gain vs its 12-month average pace.
Relative Volume (RVOL)
Low Volume
Very little activity today. Thin trading can exaggerate price moves in either direction. As reflected in the Relative Volume (RVOL) below.
- Name
- Intellia Therapeutics, Inc.
- Founded
- 2014
- CEO
- John M. Leonard
- Employees
- 377
- Fiscal Year End
- Dec 31, 2024
- Address
57 Cambridge Parkway, Suite 200A
Cambridge
Massachusetts
02142
United States
- GICS Classification
- Health Care›Pharmaceuticals, Biotechnology & Life Sciences›Biotechnology
- Website
- www.intelliatx.com
Related Heatmaps
Cathie WoodPortfolio ARK Investment Management |